Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds
Executive Summary
Merck/Schering-Plough's Vytorin is likely to have favorable formulary coverage with approximately 38% of managed care payors within the first year of launch, according to a survey by Prudential Equity Group
You may also be interested in...
Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority
Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York
Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority
Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York
Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor
Merck/Schering-Plough's cholesterol-lowering agent Vytorin will carry a wholesale acquisition cost that is a 22% discount to the three highest doses of Pfizer's Lipitor